Here we aimed to determine if ETV:IDS could still be effective at reducing Nf-L if treatment was initiated at 4.5 months of age, a stage in disease progression when CSF Nf-L levels are substantially more elevated, which is more representative of when treatment onset might be initiated in patients with MPS II. This evidence concerns the gene NEFL and mucopolysaccharidosis type 2.